Claims
- 1. A process for the hydroformylation of ethylenically unsaturated compounds, in which at least one ethylenically unsaturated compound is reacted with carbon monoxide and hydrogen in the presence of a ligand-metal complex of ruthenium, rhodium, palladium, iridium and/or platinum, where the ligand-metal complex comprises a monophosphine, monophosphinite or monophosphineamiditewherein the ligand has the formula II where X are each, independently of one another O or NR, R are each, independently of one another, hydrogen, alkyl, cycloalkyl, haloalkyl, aryl or aralkyl and R′ is hydrogen, alkyl, cycloalkyl, aryl, aralkyl, alkoxy, cycloalkoxy, aryloxy, aralkyloxy, alkylamino, di(alkyl)amino, cycloalkylamino, N-cycloalkyl-N-alkylamino, di(cycloalkyl) amino, arylamino, N-aryl-N-alkylamino, di(aryl)amino, aralkylamino, N-aralkyl-N-alkylamino, N-aralkyl-N-arylamino, di(aralkyl)amino, acyl or carbamoyl.
- 2. A process as claimed in claim 1, wherein the radicals R are each, independently of one another, methyl, t-butyl, trifluoromethyl or phenyl.
- 3. A process as claimed in claim 2, wherein the ligand is selected from among2-cyclohexyl-2-phospha-1,3,5,7-tetramethyl-6,9,10-trioxatricyclo[3.3.1.1{3,7}decane, 2-octyl-2-phospha-1,3,5,7-tetramethyl-6,9,10-trioxatricyclo[3.3.1.1 {3,7}]decane, 2-phenyl-2-phospha-1,3,5,7-tetramethyl-6,9,10-trioxatricyclo[3.3.1.1 {3,7}]decane, 2-t-butyl-2-phospha-1,3,5,7-tetramethyl-6,9,10-trioxatricyclo[3.3.1.1 {3,7}]decane 2-phospha-1,3,5,7-tetramethyl-6,9,10-trioxatricyclo[3.3.1.1 {3,7}]decane.
- 4. A process as claimed in claim 1, wherein at least one compound of the formula III or IV, whereRa are, independently of one another, radicals different from hydrogen and Rb is hydrogen or a radical different from hydrogen, is used as ethylenically unsaturated compound.
- 5. A process as claimed in claim 4, wherein an oligo(C3-C5-alkene) or poly(C3-C6-alkene) is used as ethylenically unsaturated compound.
- 6. A ligand-metal complex comprising a metal selected from among ruthenium, rhodium, palladium, iridium and/or platinum and at least one monophosphine, monophosphinite or monophosphinamiditewherein the ligand has the formula II where X are each, independently of one another O or NR, R are each, independently of one another, hydrogen, alkyl, cycloalkyl, haloalkyl, aryl or aralkyl and R′ is hydrogen, alkyl, cycloalkyl, aryl, aralkyl, alkoxy, cycloalkoxy, aryloxy, aralkyloxy, alkylamino, di(alkyl)amino, cycloalkylamino, N-cycloalkyl-N alkylamino, di(cycloalkyl) amino, arylamino, N-aryl-N-alkylamino, di(aryl)amino, aralkylamino, N-aralkyl-N-alkylamino, N-aralkyl-N-arylamino, di(aralkyl)amino, acyl or carbamoyl.
Priority Claims (1)
Number |
Date |
Country |
Kind |
100 23 468 |
May 2000 |
DE |
|
Parent Case Info
This application is a 371 of PCT/EP01/05404 filed May 11, 2001.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/EP01/05405 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO01/85661 |
11/15/2001 |
WO |
A |
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
3050531 |
Epstein et al. |
Aug 1962 |
A |
6037500 |
Zhang |
Mar 2000 |
A |
Foreign Referenced Citations (2)
Number |
Date |
Country |
1 573 422 |
Aug 1980 |
GB |
9842717 |
Oct 1998 |
WO |
Non-Patent Literature Citations (2)
Entry |
XP-001010653, Gee et al. CHem.Comm.1999,901-902. |
Organometallics 2000, 19, 2791-3796 XP-002173920, Carraz et al. |